Five comparative cohorts to assess the risk of genital tract infections associated with sodium-glucose cotransporter-2 inhibitors initiation in type 2 diabetes mellitus.

Abstract

AimTo assess the association between SGLT‐2 inhibitors initiation and genital tract infections (GTIs) among patients with type 2 diabetes.MethodsA population‐based cohort study using administrative healthcare data from Alberta, Canada, and primary care data from the UK’s Clinical Practice Research Datalink (CPRD). Among new metformin users, we identified new users of SGLT‐2 inhibitors and five active comparator cohorts (new users of dipeptidyl peptidase‐4 (DPP‐4) inhibitors, sulfonylureas (SU), glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA), thiazolidinediones (TZD) and insulin). The outcome of interest was a composite GTI outcome. In each cohort, we used high‐dimensional propensity score matching to adjust for confounding and conditional Cox proportional hazards regression to estimate the hazard ratios (HR). We used random‐effects meta‐analysis to combine aggregate data across databases.ResultsThe risk of GTI was higher for SGLT‐2 inhibitors users compared with DPP4inhibitor users (pooled HR 2.68, 95% CI 2.19 3.28), SU users (3.29, 2.62–4.13), GLP1‐RA users (2.51, 1.90–3.31), TZD users (4.17, 2.46–7.08) and insulin users (1.86, 1.27–2.73).ConclusionIn five comparative cohorts, SGLT‐2 inhibitors initiation is associated with a higher risk of GTIs. These findings from real‐world data are consistent with placebo‐controlled randomized controlled trials.